Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and Peripheral Microvascular Dysfunction in HFpEF
2022-501682-45-00Phase 4Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of empagliflozin in heart failure with preserved ejection fraction (HFpEF), sponsored by Maastricht University Medical Center+. Primary endpoint: Cutaneous vascular conductance (CVC) by LASCA. Started Nov 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2022-501682-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501682-45-00.